KRAS and non-small cell lung carcinoma: Another retrospective study evaluating the clinical outcomes of first-line pembrolizumab according to the KRAS and TP53 statuses among 696 patients with ≥ 50% PD-L1-positive NSCLC reported that TP53 mutation increased the response rates, PFS, and OS in a KRAS-mutant population but not in a KRAS-wild-type population [26].